Skip to content
10-Q

Quarterly Report

Phio Pharmaceuticals Corp PHIO

0001437749-26-015604

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 11.62M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $2K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.28M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $17.03M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $21.03M
Stockholders Equity Q1 2026 · Mar 31, 2026 $16.46M
Stockholders Equity Q1 2026 · Dec 31, 2025 $20.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 $12.17M
Stockholders Equity Q1 2026 · Dec 31, 2024 $4.72M
Total Liabilities Q1 2026 · Mar 31, 2026 $950K
Total Liabilities Q1 2026 · Dec 31, 2025 $1.34M
Current Assets Q1 2026 · Mar 31, 2026 $17.4M
Current Assets Q1 2026 · Dec 31, 2025 $21.48M
Total Assets Q1 2026 · Mar 31, 2026 $17.41M
Total Assets Q1 2026 · Dec 31, 2025 $21.49M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.34
Eps Basic Q1 2026 · Mar 31, 2025 −$0.41
Sga Expense Q1 2026 · Mar 31, 2026 $1.37M
Sga Expense Q1 2026 · Mar 31, 2025 $986K
Rd Expense Q1 2026 · Mar 31, 2026 $2.79M
Rd Expense Q1 2026 · Mar 31, 2025 $886K
Net Income Q1 2026 · Mar 31, 2026 −$4M
Net Income Q1 2026 · Mar 31, 2025 −$1.77M
Operating Income Q1 2026 · Mar 31, 2026 −$4.17M
Operating Income Q1 2026 · Mar 31, 2025 −$1.87M